Recipharm wins SwedenBIO Award
The winner of the ninth annual SwedenBIO Award was announced on Thursday night (4th June). This year Recipharm AB was honoured for its efforts and contribution to Sweden life science during the past year.
The citation reads:
Recipharm has purposefully and with great skill built a solid organisation with a critical mass. A good revenue model has contributed to that the company created jobs in Sweden, but also established itself internationally. Recipharm is an extraordinary life science company that during the year strongly contributed to an increased interest in the industry and is an inspiring example for the whole of Swedish life science industry.
The prize is awarded to a company that demonstrated achievements and success beyond the norm in the life science industry in the past year and that has contributed to an increased interest in the business.
Lars Aldersson, Chairman of SwedenBIO said “Recipharm shows that with the help of strong leadership, a responsible investment strategy and focus on quality it is possible to build a global life science company based in Sweden, something that will hopefully inspire others to similar deeds.
Thomas Eldered, CEO, commented “We are very honoured to be recognized by SwedenBIO in this way. As an international company based in Sweden we are committed to investing and developing life science talent and capability here”.
Contact information
Thomas Eldered, CEO, thomas.eldered@recipharm.com, 08-602 52 10
For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: E-mail: t.jervis@defacto.com or a.heeley@defacto.com
Tel: +44 (0) 207 861 3019/3043
About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.3 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03
www.recipharm.com
Tags:
